"The company's results for the third quarter and year-to-date 2010 reflect our success at delivering solid financial results while we continue to execute on our market and product development strategies designed to generate sustained growth for Thoratec over the long term," noted Gary F. Burbach, president and chief executive officer of Thoratec.
"Our top line performance was driven by the continued worldwide adoption of the HeartMate II® LVAS (Left Ventricular Assist System) for Bridge-to-Transplantation (BTT) and Destination Therapy (DT). At the same time, we continued to achieve solid operating leverage as reflected by our earnings performance."
The company indicated that it ended the quarter with 242 HeartMate II centers globally, an increase of 31 centers through the first nine months of 2010, with 181 centers worldwide now utilizing its new HeartMate peripherals, which are providing important quality of life benefits to patients and generating incremental revenue growth.
"Helping to drive our near-term financial performance and market leadership position for the future are investments in our field organization and market development programs that are generating referral activity among cardiologists, while providing centers support in areas including reimbursement and clinical best practices," Burbach said.
Burbach noted that the FDA has approved a label change for the HeartMate II incorporating the data from the company's BTT post-approval study that showed survival of 90 percent at six months and 85 percent at one year. "The outcomes from this study also reflected continued improvements in several important adverse event categories among HeartMate II patients, including zero device replacements and lower reported rates of bleeding, stroke and right heart failure," he commented.
"In addition, we continue to see the release of favorable HeartMate II data
|SOURCE Thoratec Corporation|
Copyright©2010 PR Newswire.
All rights reserved